title: [Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
abstract: There are no reports comparing the efficacy of 3 selective 5-HT(3) receptor antagonists (Granisetron, Ondansetron, and Ramosetron). We designed a prospective study to compare the efficacy of Granisetron, Ondansetron, and Ramosetron. Thirteen patients gave informed consent to participate in the study. We assigned them to groups taking Granisetron, Ondansetron, or Ramosetron before the high-dose chemotherapy. They themselves reported the extent of their nausea and how many times they vomited per day from the first to the sixth day of chemotherapy. We evaluated their report with PLS (Partial Least Squares) and Welch's t-test. From the results of PLS, it was suggested that CDDP contributed the most and Ramosetron the least to the extent of nausea, while Doxorubicin (ADM)/CDDP contributed the most and Ramosetron the least to the frequency of vomiting. Then we compared the antiemetic effect of the agents regarding the types of chemotherapy. It was concluded that Ramosetron might have been the most effective of the three agents in reducing nausea and vomiting, but with no significant difference.
authors.affiliation: Dept. of Hospital Pharmacy, Osaka University.
authors.forename: Miki
authors.initials: M
authors.lastname: Takenaka
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Okamoto
authors.forename: Kenji
authors.initials: K
authors.lastname: Ikeda
authors.forename: Ryo
authors.initials: R
authors.lastname: Hashimoto
authors.forename: Takafumi
authors.initials: T
authors.lastname: Ueda
authors.forename: Nobuo
authors.initials: N
authors.lastname: Kurokawa
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Takagi
authors.forename: Etsuko
authors.initials: E
authors.lastname: Uejima
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D017829:Granisetron / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control*; D017294:Ondansetron / Q000627:therapeutic use; D012516:Osteosarcoma / Q000188:drug therapy*; D011446:Prospective Studies; D058831:Serotonin 5-HT3 Receptor Antagonists; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D001562:Benzimidazoles; D002945:Cisplatin; D004317:Doxorubicin; D017829:Granisetron; D007069:Ifosfamide; D017294:Ondansetron; D058831:Serotonin 5-HT3 Receptor Antagonists; C071315:ramosetron